Immuron delivers another year of strong sales growth
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
In delivering its annual report on Friday, Immuron Ltd (ASX:IMC) provided a promising update in relation to its various activities in the health and biotech sectors.
The group's principal activity is oral immunotherapy research and development and product sales focused on bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases.
Product sales comprise the well-established Travelan and Protectyn, used for the prevention of travellers’ diarrhoea.
Travelan is Immuron’s over-the-counter gastrointestinal and digestive health supplement, and global sales increased by 29.5% year-on-year in fiscal 2019 to $2.39 million.
Australian sales increased 14% to $1.22 million, a good performance given this is a more established market for the product.
Increased initiatives in the pharmacy sector, including television advertising with Chemist Warehouse and stronger merchandising in-store, contributed to this sales momentum.
Travelan cracks the $1 million mark in the US
In the US, Travelan sales also spiked dramatically with fiscal 2019 revenue exceeding the $1 million milestone for the first time, as sales grew strongly by 32% year-on-year to $1.02 million.
The company’s partnership with Passport Health, America’s largest travel medicine network, and rising sales on the Amazon platform was central to this performance.
During fiscal 2019, Immuron collaborated with the US Department of Defense, focusing on research and development initiatives in relation to Shigella research.
Shigella is the bacterium responsible for the onset of dysentery.
Immuron’s associates at the Armed Forces Research Institute of Medical Sciences (AFRIMS), a Bangkok-based laboratory of the Walter Reed Army Institute of Research (WRAIR), performed the research.
Dr Robert Kaminski, a senior scientist with WRAIR said, ‘’The study results clearly demonstrated that animals with severe inflammation in the gastrointestinal tract and high inflammatory cytokines in fecal samples were associated with severe dysentery and that prophylactic administration of Travelan significantly reduced the inflammatory response ... the combination of our Shigella vaccine research and development efforts with Immuron’s oral immunotherapy platform make [sic] perfect sense.’’
The World Journal of Gastroenterology reports an estimated 1.5 billion annual episodes of diarrhoea worldwide.
They lead to the deaths of about 2.2 million people, mostly children in developing countries.
Authorities believe Shigella causes 80 to 165 million cases of disease worldwide, leading to about 600,000 deaths annually.
Looking to the future, three Immuron Shigella-specific therapeutic products will now go on to evaluation in WRAIR’s pre-clinical models of shigellosis.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.